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ABSTRACT: The nickel-dependent enzyme urease is a virulence factor for a large number of critical human pathogens, making this 
enzyme a potential target of therapeutics for the treatment of resistant bacterial infections. In the search for novel urease inhibitors, 
five selected coordination and organometallic Au(III) compounds containing N^N or C^N and C^N^N ligands were tested for their 
inhibitory effects against Canavalia ensiformis (jack bean) urease. The results showed potent inhibition effects with IC50 values in 
the nanomolar range. The 2.14-Å resolution crystal structure of Sporosarcina pasteurii urease inhibited by the most effective Au(III) 
compound [Au(PbImMe)Cl2]PF6 (PbImMe = 1-methyl-2-(pyridin-2-yl)-benzimidazole) reveals the presence of two Au ions bound 
to the conserved triad αCysγββ/αHisγβγ/αεetγ67. The binding of the Au ions to these residues blocks the movement of a flap, 
located at the edge of the active site channel and essential for enzyme catalysis, completely obliterating the catalytic activity of urease. 
Overall, the obtained results constitute the basis for the design of new gold complexes as selective urease inhibitors with future 
antibacterial applications.
Several metals and metal-based compounds have been used for 
centuries as anti-infective agents on a simple empirical basis 
with some appreciable results. For instance, gold cyanide was 
proposed by Koch as an antitubercular agent in the pioneering 
times of modern pharmacology.1 Since then, remarkable pro-
gress has been made on the development of gold complexes as 
therapeutic agents, starting from the anti-arthritis agent aurano-
fin (AF) [2,3,4,6-tetra-o-acetyl-L-thio--D-glucopyranosato-S-
(triethyl-phosphine)Au(I)]. Recently, this drug is receiving in-
creasing attention for its potential to be repurposed as anti-
cancer, antiparasitic and antibacterial agent,2-4 leading to the de-
velopment of novel gold-based antibacterial agents acting as 
specific inhibitors of several important enzymes.4-12 
For example, a family of Au(I)-based phosphine complexes 
were tested and compared with AF toward a representative 
panel of pathogens that included Gram-positive, Gram-negative 
and Candida strains,13 and showed activity on Gram-positive 
strains. More recently, organometallic Au(I) N-heterocyclic 
carbene (NHC) complexes were reported as effective antibacte-
rial agents towards Gram-positive bacteria.9, 14-16 Despite an in-
creasing number of studies, the precise mechanism of the anti-
microbial action of Au(I) complexes and their biomolecular tar-
gets are unknown. Due to the reported inhibition on the mam-
malian seleno-enzyme thioredoxin reductase (TrxR) by AF and 
Au(I) NHCs complexes, with formation of a stable Au-selenol 
adduct at the active site of the protein,17 it was hypothesized that 
this enzyme could also be responsible for the observed antibac-
terial effects. However, the bacterial TrxRs lack the ‘aurophilic’ 
selenol active site,18 and this may account for the reduced affin-
ity of Au(I) binding with respect to mammalian TrxRs. 
Within this framework, only rare studies on the possible use of 
Au(III) complexes as targeted inhibitors of bacterial enzymes 
have appeared so far. For example, phosphorous dendrimers 
bearing iminopyridino-end groups coordinating to Au(III) ions 
were reported to inhibit the growth of both Gram-positive and 
Gram-negative bacterial strains.19 Moreover, moderate antibac-
terial activity of Au(III) complexes with different L-histidine-
containing dipeptides was described,20 but no mechanistic in-
vestigation was conducted to rationalize the observed biological 
effects. In general, Au(III) complexes have less affinity and se-
lectivity for TrxRs binding,21 while they appear to target differ-
ent types of mammalian proteins, including zinc finger pro-
teins,22, 23 water/glycerol channels,24, 25 the proteasome26 and 
phosphatases,27 among others. 
An emerging target for bacterial infections is urease (urea ami-
dohydrolase, E.C. 3.5.1.5), a nickel-dependent enzyme found in 
a large variety of organisms28-32 and featuring a bimetallic 
Ni(II)-containing reaction site.29, 30, 32 Urease is involved in the 
global nitrogen cycle, catalyzing the rapid hydrolytic decompo-
sition of urea to eventually yield ammonia and carbonate,33, 34 
consequently causing a pH increase that has negative effects 
both on agriculture35 and human health.36 For instance, ten of 
the twelve antibiotic-resistant priority pathogens listed in 2017 
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by the World Health Organization (WHO) are ureolytic bacteria 
for which urease is a virulence factor.37 Moreover, mixed spe-
cies infections are more difficult to treat because of an increased 
tolerance to antimicrobials.36 The general high significance 
given by the WHO to the antimicrobial-resistance priority, sup-
ported by the Global Antimicrobial Resistance Surveillance 
System (GLASS),38 imposes urease to the attention of the re-
searchers as a target to develop new drugs for the treatment of 
important bacterial infections acting as a threat to public health 
worldwide. Moreover, the very high structure conservation of 
ureases from plants and bacteria warrants the possibility to ex-
tend the results obtained in the pharmaceutical and medical ap-
plications to the agro-environmental field, for which an exces-
sive urease activity also represents a negative aspect.28-32 
A large number of urease inhibitors such as ȕ-mercapto-etha-
nol,39 phosphate,40 sulfite,41 fluoride,42 as well as hydroxamic,43 
citric44 and boric45 acids, 1,4-benzoquinone46 and catechol,47 di-
amido-phosphate and monoamido-thiophosphate originated, re-
spectively, by urease-catalyzed hydrolysis of phe-
nylphosphorodiamidate (PPD)48 or N‐(n‐butyl)thiophosphoric 
triamide (NBPT)49 have been studied and the structural details 
of their modes of action have been elucidated. Additionally, 
metal ions such as Co(II), Ni(II), Cu(II), Zn(II), Cd(II), Pb(II), 
Hg(II) and Ag(I) are also good urease inhibitors.50-52 Within this 
context, the efficacy of Ag(I) as a urease inactivator has been 
recently rationalized by the structural determination of its ad-
duct with Sporosarcina pasteurii (S. pasteurii) urease (SPU).53 
Ag(I) deactivates urease by forming a dinuclear cluster of two 
Ag(I) ions bound to the largely conserved triad 
αCys322/αHis323/αMet367, thus blocking the movement of a 
structural motif (mobile flap), essential for urease activity, con-
sequently inhibiting the catalytic activity of the enzyme. Re-
markably, no Au compound has ever been tested as urease in-
hibitor so far. 
We report here on a urease inhibition activity screening of se-
lected Au(III) complexes with bidentate N-donor ligands or cy-
clometalated C^N and C^N^N scaffolds (compounds 1-5, Fig-
ure 1). In detail, two coordination complexes with (pyridyl)ben-
zimidazole type ligands – [Au(PbIm)Cl2] (1) (PbIm = 2-(pyri-
din-2-yl)-benzimidazole)54 and [Au(PbImMe)Cl2]PF6 (2) 
(PbImMe = 1-methyl-2-(pyridin-2-yl)-benzimidazole),24 re-
spectively, were selected. Moreover, three organometallic 
Au(III) compounds featuring the C^N cyclometalated 2-ben-
zylpyridine (pyb-H) ligand (3)55 and N-phenylpyridin-2-amine 
(phepya) ligand (4),56 as well as the tridentate C^N^N ligand 6-
(1,1-dimethylbenzyl)-β,β’-bipyridine (bipydmb) (5)57 were also 
examined. The compounds were synthesized according to pre-
viously reported procedures.24, 54-57 The Au(III) compounds 
were tested for their inhibitory effects against Canavalia ensi-
formis (jack bean) urease (JBU) in vitro, and the structure of the 
adduct obtained upon incubation of compound 2 with SPU was 
determined by X-ray diffraction crystallography. Model coor-
dinates and structure factors were deposited in the Protein Data 
Bank (PDB) under the accession code 6I9Y. 
 
 
Figure 1. Schematic structures of Au(III) complexes tested for ure-
ase inhibition. 
Kinetics of JBU inhibition with Au(III) compounds. The ef-
ficiency of urease inhibition by compounds 1-5 was tested by 
incubating JBU for 1 h in the presence of increasing concentra-
tions of the different compounds, in order for the enzyme-inhib-
itor complex to reach a steady-state condition. Subsequently, 
the activity of urease was determined (see Supplementary In-
formation for experimental details). Plots of the reaction rate 
after incubation, normalized vs. the reaction rate of the non-
treated enzyme, as a function of inhibitor concentration, show a 
sigmoidal distribution (Figure 1-SI). A fit of the data to the ca-
nonical equation to obtain the inhibitor concentrations bringing 
about 50% inactivation of the enzyme (IC50) yielded similar val-
ues for compounds 1-5, in the low-nanomolar concentration 
range (Table 1). The most potent inhibitor is the cationic coor-
dination complex 2, while the bidentate neutral N^N compound 
1 and the cyclometalated C^N derivatives 3 and 4 are ca. 2-fold 
less active. This observation suggests that non-covalent gold 
complex-urease adduct formation, involving electrostatic inter-
actions between the two partners, may be instrumental to facil-
itate Au(III) coordinative binding.58 In line with previous stud-
ies on the reactivity of cyclometalated complexes with pro-
teins,59 the Au(III) C^N^N complex 5 is the least efficient of the 
series. Notably, the urease inhibition strength of the Au(III) 
compounds is comparable to that observed for other metal ions 
(namely, Hg(II), Ag(I) and Cu(II)) and two-three orders of mag-
nitude greater than in the case of Zn(II), Cd(II), Ni(II), Pb(II) 
and Co(II).50-52 However, the advantage of using coordination 
or organometallic compounds allows the fine-tuning of the 
properties of the respective Au(III) complexes, reduces their 
speciation in aqueous solution, and allows for further optimiza-
tion of the selectivity properties for a certain target. 
 
Table 1. Values of IC50 for the inhibition of jack bean urease 
(JBU) by compounds 1-5 in Figure 1 
Compound Type of ligand IC50 (nM) 
1 N^N 18 ± 1 
2 N^N 9.0 ± 0.2 
3 C^N 14.9 ± 0.5 
4 C^N 16.4 ± 0.5 




X-ray structure of SPU inactivated by a selected coordina-
tion Au(III) complex. The X-ray crystal structure of SPU co-
crystallized in the presence of the best urease inhibitor, specifi-
cally the cationic Au(III) compound 2  (PDB code 6I9Y, see 
Supplementary Information for experimental details; data col-
lection, processing and refinement statistics for Au-inhibited 
SPU are provided in Table 1-SI) shows the well-described het-
eropolymeric nature of S. pasteurii urease, consisting of an 
(αȕȖ)3 quaternary structure. The similarity of the protein scaf-
fold with respect to native urease (PDB code 4CEU)42 is con-
firmed by the RεSD between their Cα atoms (0.29, 0.25 and 
0.β0 Å for the α, ȕ and Ȗ subunits, respectively). A more detailed 
analysis of the Cα RMSD (Figure 2-SI) reveals that the ȕ and Ȗ 
subunits show a largely invariant backbone with respect to that 
of the native enzyme, whereas three portions of the α subunit, 
containing the Ni-bound active-site, are affected by signifi-
cantly larger displacements: i) a region including residues 390-
400, located on a surface patch showing a large conformational 
variability among the SPU structures determined so far, with 
RMSD values up to ca. 0.9 Å, ii) a region including residues 
310-340, which corresponds to the mobile helix-turn-helix mo-
tif (mobile flap) responsible for the substrate access into the ac-
tive site of urease, with RMSD up to ca. 1.4 Å, and iii) the re-
gion including residues 548-555, which forms a solvent ex-
posed loop at the C-terminal portion of the α subunit, with 
RMSD up to ca. 1.2 Å. 
The overall framework of the Ni-containing active site region 
of the refined model is highly conserved with respect to the na-
tive enzyme,42 as revealed by the well-defined electron density 
represented in Figure 2. 
 
 
Figure 2. Atomic model of the active site of SPU inhibited in the 
presence of compound 2. The nickel-coordination environment is 
shown super-imposed on the final 2Fo − Fc electron density map 
contoured at 1σ (cyan). Carbon, nitrogen, oxygen and nickel atoms 
are light grey, blue, red and green, respectively. 
The two Ni(II) ions, distant 3.6 Å apart, are bridged by the car-
boxylate group of the carbamylated αδysββ0* residue, which is 
bound to Ni(1) and Ni(β) by Oθ1 and Oθβ, respectively. Ni(1) 
is additionally coordinated by αHisβ49 Nį and by αHisβ75 Nİ, 
whereas Ni(β) is further bound to αHis1γ7 Nİ, αHis1γ9 Nİ and 
αAspγ6γ Oį1. The tetrahedral cluster of four water molecules 
in the vicinity of the Ni(II) ions that, in the native urease, are 
substituted by substrate urea during the enzyme catalytic cycle, 
are also not perturbed in the presence of the inhibitor. The dis-
tances and angles around the Ni(II) ions in the SPU inhibited by 
compound 2 are largely indistinguishable from those observed 
in native and Ag(I)-inactivated SPU structures53 (Table 2-SI). 
The unbiased omit electron density map reveals two additional 
spherical electron densities located in the vicinity of the mobile 
flap, around the αCysγββ thiol, the αHisγβγ imidazole, and the 
αεetγ67 thioether functionalities (Figure 3A). The strong 
anomalous difference Fourier electron density maps associated 
to those 2Fo-Fc electron densities suggested the presence of two 
Au atoms in this region (Figure 3A). The coordination environ-
ment around the two Au atoms bound to the His-Cys-Met triad 
(Figure 3A and 3B) involves His323 N and to Cys322 
Sfor Au(1), and Cys322 S and Met367 S for Au(2) (Fig-
ure 3B; all distances and angles around the Au atoms are re-
ported in Table 3-SI). The two Au ions are bridged by Cys322 
S and are separated by 3.27 Å.  
 
Figure 3. (A) Atomic model of the Ni(II)-containing active site of 
SPU inhibited in the presence of compound 2, together with the 
region affected by Au(I) binding (PDB code 6I9Y). The model for 
the latter region is shown superimposed onto the final 2Fo − Fc elec-
tron density map contoured at 1σ (cyan). The unbiased Fo − Fc omit 
map is shown contoured at 3.0 σ (orange). The anomalous differ-
ence electron density map contoured at 3.0 σ is also shown (dark 
blue). (B) Coordination environment of the Au(I) dinuclear cluster 
in the structure of SPU inhibited in the presence of compound 2. 
The occupancy of the gold atoms is 0.85. Carbon, nitrogen, oxygen, 
nickel and gold atoms are light grey, blue, red, green and dark grey, 
respectively. 
The quasi-linear geometric arrangement of the ligands is com-
patible with the presence of two Au(I) ions. This conclusion is 
also supported by previously reported electrochemical studies 
of compound 2, which features a reduction potential for the 
AuIII/I reduction process Ered = -0.33 V,24 demonstrating the pos-
sibility for the complex to undergo reduction in biological en-
vironment. The short Au ••• Au distance (3.27 Å), the small 
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Au(1) - αCys322 SȖ – Au(2) angle (73.2°) and the slight distor-
tion of the αHis323 Nį – Au(1) – αCys322 SȖ and αCys322 SȖ 
– Au(2) – αMet367 Sį angles (166.4° and 159.5°, respectively), 
caused by a bowing effect of the two Au atoms towards each 
other, are strong indications of the presence of an aurophilic in-
teraction between the two Au(I) ions.60 
A third electron density was observed close to αCys555 S in 
the C-terminal portion of the α chain, also featuring a strong 
anomalous signal suggesting the presence of a third Au atom in 
that region. This Au(3) atom resides in a position 25-27 Å dis-
tant from the Ni(II) ions in the active site, with no evident in-
fluence on the catalytic mechanism. The oxidation state of this 
atom cannot be established with certainty based on the coordi-
nation geometry, because no electron density clearly attributa-
ble to ligands other than the side chain thiol sulfur atom can be 
observed, even though the presence of additional ligands, such 
as disordered water molecules, cannot be excluded. 
The protein backbone of urease in the vicinity of the active site 
flap is strongly affected by the presence of the two Au ions, 
compared to the structure of the native enzyme (Figure 4), in a 
similar manner to that of Ag(I)-inhibited urease.53 Specifically, 
the region around the Au-binding αCysγββ and αHisγβγ, resi-
dues belonging to the mobile flap, features RMSD values for 
the backbone Cα atoms with respect to the corresponding atoms 
of native SPU that are significantly larger than the average for 
the unbound enzyme (Figure 2-SI). The thiolate SȖ atom of 
αCysγββ and the imidazole ring of αHisγβγ are shifted by ca. 
2.3 Å and 1.2 Å, respectively, in order to coordinate the two Au 
ions (Figure 4). The Au(2) ion also provides the establishment 
of a covalent bridge between the mobile flap, with αCysγββ and 
αHisγβγ, and the more rigid portion of the protein that hosts 
αεetγ67, with its Sį shifted by 0.γ Å (Figure 3). 
 
 
Figure 4. Ribbon diagram of a close-up of the structure of SPU 
inhibited in the presence of compound 2 (PDB code 6I9Y) in the 
vicinity of the active site region, showing the position of the mobile 
flap; the ribbon is colored according to the RMSD calculated with 
respect to the native enzyme (PDB code 4CEU) (red: RMSD > 1; 
pink: 0.5 < RMSD < 1; white: RMSD = 0.5; blue: RMSD < 0.5). 
The Ni and Au atoms are shown as green and gold spheres, respec-
tively. The transparent atoms show the conformation of the side 
chain of the residues Cys322, His323 and Met367 in the native 
enzyme. 
Overall, we have shown here that the Au(III) complexes 1-5 are 
able to potently inhibit urease. Moreover, we have also struc-
turally characterized by X-ray diffraction, for the first time, the 
adduct of Au ions with essential residues in the vicinity of the 
urease active site, elucidating the mechanism of inhibition at a 
molecular level. In the case of coordination compounds with 
bidentate N^N ligands, the binding directly involves residues 
likely to impair the enzymatic mechanism via alterations of the 
overall protein structure. The lack of the organic ligand in the 
crystal structure of SPU inhibited by compound 2, leaving only 
two naked Au ions bound to the conserved Cys-His-Met triad, 
suggests the presence of several successive steps of ligand sub-
stitutions and metal reduction leading to the final structure ob-
served in the solid state. As observed for previously reported 
Au(III)/protein adducts, this type of compounds favors ex-
change of the original ligands and further possible reduction to 
Au(I) species.61-63 
It is worth mentioning that so far only a few X-rays structures 
of gold complexes (Au(I) and Au(III)) with proteins have been 
reported,64 where these metal ions bind to Cys,65 66 Lys,67 or His 
residues.68 Further studies are necessary to validate the binding 
mode of the cyclometalated Au(III) complexes to urease. In this 
case, retention of the cyclometalated ligands may be envisaged 
upon protein adduct formation,23 which would be essential to 
design urease-targeted inhibitors. Finally, our results hold 
promise for the screening of the antibacterial properties of 
Au(III) complexes in ureolytic microorganisms, including My-
cobacterium tuberculosis, Helicobacter pylori, Yersinia pestis 
and Cryptococcus neoformans. 
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